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Background: Electroconvulsive therapy (ECT) has been used for treatment-resistant depression. 
However, predictors of response to ECT have not been adequately studied using the   Montgomery 
and Åsberg Depression Rating Scale, especially in older patients with treatment-resistant 
depression.
Methods: This study included 18 Japanese patients who fulfilled the Diagnostic and Statistical 
Manual of Mental Disorders Fourth Edition Text Revision criteria for a diagnosis of major 
depressive disorder or bipolar disorder with a current major depressive episode, and met the 
definition of treatment-resistant depression outlined by Thase and Rush, scoring $21 on the 
Montgomery and Åsberg Depression Rating Scale. The three-factor model of the Montgomery 
and Åsberg Depression Rating Scale was used for analysis. Factor 1 was defined by three 
items, factor 2 by four items, and factor 3 by three items, representing dysphoria, retardation, 
and vegetative symptoms, respectively. ECT was performed twice a week for a total of six 
sessions using a Thymatron System IV device with the brief pulse technique. Clinical responses 
were defined on the basis of a $50% decrease in total pretreatment Montgomery and Åsberg 
Depression Rating Scale scores.
Results: The mean pretreatment factor 2 score for responders (n = 7) was significantly 
lower than that for nonresponders (n = 11). Furthermore, a significant difference in mean 
factor 3 score between responders and nonresponders was observed one week after six sessions 
of ECT, indicating a time lag of response. No significant differences were observed for age, 
number of previous episodes, and duration of the current episode between responders and 
nonresponders.
Conclusion: This study suggests that a low pretreatment factor 2 score is a good predictor of 
response to ECT in older patients with major depression.
Keywords: factor analysis, electroconvulsive therapy, refractory depression, Montgomery and 
Åsberg Depression Rating Scale, predictors of response
Introduction
Electroconvulsive therapy (ECT) has been used for treatment-resistant depression. 
In a recent report, 50%–60% of patients with treatment-resistant depression responded 
to ECT.1,2 Response rates have also been reported for older patients. For example, Tew 
et al reported that adult patients ($59 years of age) had a significantly lower rate of 
response than young-older patients (60–74 years), while old-older patients ($75 years) 
had an intermediate rate of response.3 There has been some concern about factors 
predictive of response to ECT in the treatment for depression, and symptom predic-
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Scale (MADRS) have not been well studied,   especially in old 
patients with treatment-resistant depression.
The MADRS is a 10-item clinical rating scale that 
measures the severity of several depressive symptoms.4 
Recently, Suzuki et al5 analyzed pretreatment MADRS scores 
in 132 Japanese patients with major depressive disorder and 
followed the three-factor model of the MADRS: factor 1, 
defined by three items representing dysphoria, ie, reported 
sadness, pessimistic thoughts, and suicidal thoughts; factor 2, 
defined by four items representing retardation, ie, lassitude, 
inability to feel, apparent sadness, and concentration 
difficulties; and factor 3, defined by three items representing 
vegetative symptoms, ie, reduced sleep, reduced appetite, 
and inner tension.
Our recent preliminary research suggested that a higher 
score on factor 1 was a good predictor of response to ECT 
in patients with treatment-resistant depression.6 We recruited 
a further group of old patients and reanalyzed the effects of 
differences in response to ECT in old patients with treatment-
resistant depression (n = 18) by using the three-factor 
MADRS structure proposed by Suzuki et al.5
Methods
subjects
This study was conducted at St Marianna University School 
of Medicine between March 2008 and January 2009. We 
included 18 Japanese patients who fulfilled the Diagnostic and 
Statistical Manual of Mental Disorders Fourth Edition Text 
Revision (DSM-IV) criteria for a diagnosis of major depressive 
disorder (n = 16) or bipolar disorder (n = 2) with a current major 
depressive episode, and had a total pretreatment MADRS 
score $21. Patients with other axis I disorders (including 
schizophrenia, dementia, substance abuse, dysthymia, panic 
disorder, obsessive-compulsive disorder, and generalized 
anxiety disorder) and axis II disorders, as determined by 
a clinical interview, were excluded. Patients with severe 
nonpsychiatric physical disease were also excluded. Cognitive 
deficits were evaluated by mini-mental state examination, and 
patients with a pretreatment score #23 were also excluded.
Patients aged 60–83 years for whom ECT was planned 
were entered in the study. An independent psychiatrist 
recommended ECT because of drug resistance, according 
to clinical judgment. Drug resistance was defined as failure 
to respond to at least three courses of antidepressant 
medication of adequate dose and duration (ie, the stage 3 
definition of Thase and Rush).7 Patients were maintained 
on the same drug treatment for at least one week before 
ECT and during the entire study period. This study was 
approved by the bioethics committee of the St Marianna 
University School of Medicine. The purpose of the study 
and its methods were explained to all patients and their 
families, and written informed consent was obtained from 
all participants.
ecT treatment
A medical history and physical examination, together with 
routine blood and urine investigations, an electrocardiogram, 
a cerebral computed tomography scan, and a chest film 
were used to screen for general medical conditions. Patients 
were anesthetized with propofol 1.0–1.5 mg/kg, and muscle 
  relaxation was achieved using suxamethonium 0.8–1 mg/kg. 
ECT was performed between 9.30 am and 11.30 am using a 
brief bipolar pulse from a constant-current Thymatron System 
IV machine (Somatics Inc, Lake Bluff, IL). ECT was given 
twice a week over six sessions. The number of ECT sessions 
was based on a report by Weiner et al.8 If the response was 
inadequate at the end of the assessment period, further ECT 
sessions were added by the treating   psychiatrist. Seizure thresh-
old was determined at the first treatment using an empirical 
titration procedure.9 Stimulus electrode placement was on the 
bifrontotemporal scalp. ECT treatment conditions were set up 
in a preset stimulation program to “Low 0.5,” which delivers 
a 0.5 ms brief pulse that automatically adjusts the frequency 
to maximize stimulus train duration at each dose. Motor 
convulsion, electroencephalography, induced tachycardia, 
and electromyography were recorded during ECT. An ictal 
response was identified by convulsive motor activity and/or 
electroencephalographic changes. ECT was completed on the 
basis of the clinical judgment of the   treating psychiatrist.
Data collection
The characteristics and severity of depressive symptoms were 
assessed by total and three-factor scores on MADRS. The 
patients were assessed pretreatment, following six sessions 
of ECT, and one week after the final ECT session. Clinical 
responses were defined on the basis of a $50% decrease 
in total pretreatment MADRS score. An independent 
psychiatrist not directly involved in clinical management of 
the patients completed the ratings. Data were collected for 
various demographic and illness variables, including gender, 
age, number of previous depressive episodes, duration of 
current episode, presence or absence of psychotic symptoms, 
age at onset of mental illness, medication history, and 
medication during the ECT course.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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statistical analysis
The clinical characteristics of the patients, including responders 
and nonresponders, were analyzed by Chi-square test or 
unpaired t-test, as appropriate. Two-way repeated-measures 
analysis of variance was used to compare total, factor 1, factor 2, 
and factor 3 MADRS scores in responders and nonresponders 
pretreatment, post-treatment, and one week after treatment. 
In addition, a receiver-operating characteristic (ROC) analysis 
was performed to estimate the cut point for factor 2.
Results
Patient characteristics are shown in Table 1. Seven patients 
were responders and 11 were nonresponders. Mean total 
MADRS score and three-factor MADRS scores pretreatment, 
post-treatment, and one week after completion of ECT for 
the responders and nonresponders are shown in Table 2. No 
significant difference was observed in total pretreatment 
(F = 3.394, P = 0.0841), factor 1 (F = 0.211, P = 0.6525), 
and factor 3 (F = 1.149, P = 0.2998) MADRS score between 
the responders and nonresponders. However, the mean 
  pretreatment factor 2 score of the responders was significantly 
lower than that of nonresponders (F = 9.001, P , 0.05). The 
optimal cut point for the factor 2 score was 19 (sensitivity 
0.91, specificity 0.71) on the ROC curve, for which the 
value of the area under the curve was 0.82 (95% confidence 
interval 0.64–1.01).
On completion of ECT, significant differences were 
observed in total (F = 11.452, P = 0.0038), factor 1 
Table 1 clinical characteristics of total patients, responders and nonresponders
Total (n = 18) Responders (n = 7) Nonresponders (n = 11) Analysis P value
Gender (male/female) 4/14 1/6 3/8 x2 = 0.57 0.45
Age (years) 70.9 ± 6.91 72.3 ± 8.8 70.0 ± 0.6 t = 0.67 0.51
number of previous 
depressive episodes
4.2 ± 2.7 3.6 ± 2.0 4.6 ± 3.0 z = -0.54 0.59
Duration of current  
episode (months)
8.0 ± 14.4 2.7 ± 2.0 11.4 ± 17.8 z = -1.22 0.22
MADrs scores 44.7 ± 7.5 40.9 ± 9.4 47.1 ± 5.0 z = -1.40 0.16
MMse scores 25.8 ± 2.5 25.8 ± 3.1 25.8 ± 2.2 z = -0.26 0.80
Psychotic symptoms (%) 66.67 71.43 63.63 x2 = 0.12 0.73
Age at onset of mental  
illness (years)
55.72 ± 13.70 58.29 ± 13.64 54.09 ± 14.15 t = 0.62 0.54
Antidepressants  
administered
clomipramine 25–75 mg (n = 4) clomipramine 25–75 mg (n = 2)
Dosulepin 50 mg (n = 1) Dosulepin 100 mg (n = 1)
Mianserin 20 mg (n = 1) Mianserin 20–60 mg (n = 3)
Paroxetine 10 mg (n = 1) Milnacipran 50 mg (n = 2)
Paroxetine 10–20 mg (n = 2)
sertraline 100 mg (n = 1)
Notes: Data are expressed as mean ± sD; comparisons were made between the responders and nonresponders using the χ2 test, unpaired t-test, and Mann–Whitney U test.
Abbreviations: MMse, minimental state examination; MADrs, Montgomery and Åsberg Depression rating scale; sD, standard deviation.
(F = 7.258, P = 0.0160), and factor 2 (F = 14.732, P = 0.0015) 
MADRS scores between responders and nonresponders. No 
significant difference was observed for post-treatment factor 
3 (F = 4.177, P = 0.0578) MADRS score between responders 
and nonresponders.
One week after completion of ECT, significant dif-
ferences were observed in total (F = 16.345, P = 0.0009), 
factor 1 (F = 7.346, P = 0.0154), factor 2 (F = 18.536, 
P = 0.0005), and factor 3 (F = 12.726, P = 0.0026) MADRS 
scores between responders and nonresponders. As a result, 
the mean value for factor 3 (vegetative symptoms) improved 
for the first time at this point, which indicates a time lag in 
response.
Discussion
The present study shows that the mean pretreatment 
  factor 2 (retardation) score of responders was significantly 
lower than that of nonresponders. However, Hickey et al 
  suggested that the response to ECT was associated with 
severe   psychomotor disturbance in adult patients.10 Buchan 
et al also suggested that adult patients who suffered from 
  depression in which retardation and delusions were features 
had a significantly improved outcome at the end of four weeks 
of ECT treatment.11 Therefore, it may be that a lower score 
for psychomotor retardation (factor 2) is a useful index for 
predicting efficacy of ECT in older patients with depression, 
but not in younger adult patients. The optimal cut point on 
factor 2 obtained using ROC analysis might be helpful for International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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clinicians when deciding whether to use ECT in older patients 
with treatment-resistant depression.
Our recent report suggested that a higher score for fac-
tor 1 (dysphoria) is a good predictor of efficacy of ECT.7 In 
contrast with our previous study, the mean factor 1 score 
was not significantly different between responders and non-
responders in this study. The reason for this discrepancy is 
unknown. The effect of small sample is undeniable. Salzman 
reported that the cardinal sign of depression in older patients 
may be the absence of positive affect rather than the presence 
of dysphoria.12 Therefore, this discrepancy may be due to the 
absence of prominent dysphoria in depressed older patients.
There have been several studies of predictors of   efficacy of 
ECT. Some have found that a shorter duration of the   current 
episode is associated with a better response to ECT,1,13 whereas 
others have found no relationship between duration of the 
current episode and responsiveness.14,15 Our present study 
found no significant effect of duration of the current episode. 
However, it should be noted that the duration of the current 
episode in responders was relatively short compared with that 
in nonresponders; the latter group included deviated samples, 
such as patients with chronic depression or dysthymic disor-
der, so may not have been suitable for analysis. A long duration 
of depressive symptoms could explain lack of response to 
ECT. No significant difference was found between responders 
and nonresponders for psychotic symptoms. Some studies 
have suggested that psychotic features respond well to ECT, 
and that responsiveness to ECT decreases with increasing 
severity of depression,10,11,16 while others do not.17,18 We also 
failed to identify differences in age between responders and 
nonresponders with treatment-resistant depression. Petrides 
et al19 and O’Connor et al20 reported that ECT was more 
effective in older than in younger adult patients.   Therefore, it 
may be difficult to identify significant age-related differences 
between responders and nonresponders within only a group of 
older patients and with no patients under 60 years old.
In conclusion, the mean pretreatment factor 2 (retardation) 
MADRS score may be an important predictor of efficacy 
of ECT in older patients with severe treatment-resistant 
depression. One limitation of the present study was its small 
sample size, so we cannot generalize our findings to a larger 
population. To confirm and generalize our findings, more 
detailed clinical studies in larger numbers of patients are 
needed to identify symptoms which predict response to ECT 
in older patients with severe treatment-resistant depression.
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